ZA200100622B - Treatment regimen for administration of phenylacetylglutamine phenylacetylisoglutamine and or phenylacetate - Google Patents

Treatment regimen for administration of phenylacetylglutamine phenylacetylisoglutamine and or phenylacetate Download PDF

Info

Publication number
ZA200100622B
ZA200100622B ZA2001/00622A ZA200100622A ZA200100622B ZA 200100622 B ZA200100622 B ZA 200100622B ZA 2001/00622 A ZA2001/00622 A ZA 2001/00622A ZA 200100622 A ZA200100622 A ZA 200100622A ZA 200100622 B ZA200100622 B ZA 200100622B
Authority
ZA
South Africa
Prior art keywords
formula
compound
pharmaceutical composition
day
group
Prior art date
Application number
ZA2001/00622A
Other languages
English (en)
Inventor
R Burzynski Stanislaw
Original Assignee
R Burzynski Stanislaw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Burzynski Stanislaw filed Critical R Burzynski Stanislaw
Publication of ZA200100622B publication Critical patent/ZA200100622B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
ZA2001/00622A 1998-07-23 2001-01-22 Treatment regimen for administration of phenylacetylglutamine phenylacetylisoglutamine and or phenylacetate ZA200100622B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
PCT/US1999/015017 WO2000004894A2 (en) 1998-07-23 1999-07-02 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Publications (1)

Publication Number Publication Date
ZA200100622B true ZA200100622B (en) 2002-06-26

Family

ID=22397538

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2001/00622A ZA200100622B (en) 1998-07-23 2001-01-22 Treatment regimen for administration of phenylacetylglutamine phenylacetylisoglutamine and or phenylacetate

Country Status (20)

Country Link
US (2) US6258849B1 (2)
EP (1) EP1098643B1 (2)
JP (2) JP2002521329A (2)
KR (4) KR100399658B1 (2)
CN (3) CN100400039C (2)
AT (1) ATE257378T1 (2)
AU (1) AU759278B2 (2)
BR (1) BR9912356A (2)
CA (1) CA2336945C (2)
DE (1) DE69914084T2 (2)
DK (1) DK1098643T3 (2)
EA (1) EA004179B1 (2)
ES (1) ES2214866T3 (2)
ID (1) ID28160A (2)
IL (1) IL140848A (2)
NZ (1) NZ509244A (2)
PL (1) PL213698B1 (2)
PT (1) PT1098643E (2)
WO (1) WO2000004894A2 (2)
ZA (1) ZA200100622B (2)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
DK1313697T3 (da) 2000-08-29 2006-04-10 Nobex Corp Immunregulatoriske forbindelser, derivater deraf samt anvendelse deraf
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
US20060058383A1 (en) * 2004-07-28 2006-03-16 Peng Huang Propyl 3-bromo-2-oxopropionate and derivatives as novel anticancer agents
SI2153870T1 (sl) * 2004-11-26 2014-05-30 Ucl Business Plc Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
HUE035921T2 (en) 2009-04-03 2018-05-28 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
CN104434894A (zh) 2009-06-08 2015-03-25 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
US8946473B2 (en) 2010-10-06 2015-02-03 Ocera Therapeutics, Inc. Methods of making L-ornithine phenyl acetate
ES2769000T3 (es) 2014-11-24 2020-06-24 Ucl Business Ltd Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco
WO2017031131A1 (en) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
JP6861708B2 (ja) * 2015-12-30 2021-04-21 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 除脂肪体重を測定するための方法
US10624869B2 (en) 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
MX389665B (es) 2017-05-11 2025-03-20 Ocera Therapeutics Inc Procesos para producir fenilacetato de l-ornitina
AU2018282735A1 (en) * 2017-06-12 2020-02-06 Stanislaw R. Burzynski Methods for the treatment of leptomeningeal disease
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472B (zh) * 2022-12-14 2024-07-26 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途
EP4731793A2 (en) * 2023-06-21 2026-04-29 Stanislaw R. Burzynski Compositions comprising antineoplastons and methods of treating pancreatic cancer
EP4731792A2 (en) * 2023-06-21 2026-04-29 Stanislaw R. Burzynski Compositions comprising antineoplastons and methods of treating lung cancer
WO2024263963A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating head and neck cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5244922A (en) * 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
ATE310505T1 (de) 1996-05-14 2005-12-15 Stanislaw R Burzynski Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität

Also Published As

Publication number Publication date
KR100399658B1 (ko) 2003-09-29
KR20010071025A (ko) 2001-07-28
CN1660061A (zh) 2005-08-31
EP1098643B1 (en) 2004-01-07
KR100417101B1 (ko) 2004-02-05
DE69914084D1 (de) 2004-02-12
WO2000004894A3 (en) 2000-04-27
ES2214866T3 (es) 2004-09-16
US6943192B2 (en) 2005-09-13
KR20030027088A (ko) 2003-04-03
CN1605334A (zh) 2005-04-13
CA2336945A1 (en) 2000-02-03
JP2002521329A (ja) 2002-07-16
IL140848A0 (en) 2002-02-10
AU4854299A (en) 2000-02-14
PT1098643E (pt) 2004-05-31
AU759278B2 (en) 2003-04-10
NZ509244A (en) 2004-02-27
EP1098643A2 (en) 2001-05-16
EA200100168A1 (ru) 2001-08-27
KR20030027087A (ko) 2003-04-03
DE69914084T2 (de) 2004-10-28
KR100414587B1 (ko) 2004-01-13
JP2011051993A (ja) 2011-03-17
DK1098643T3 (da) 2004-05-24
WO2000004894A2 (en) 2000-02-03
HK1037142A1 (en) 2002-02-01
CN1191064C (zh) 2005-03-02
PL213698B1 (pl) 2013-04-30
US20010044466A1 (en) 2001-11-22
BR9912356A (pt) 2001-04-17
KR100417100B1 (ko) 2004-02-05
ATE257378T1 (de) 2004-01-15
IL140848A (en) 2005-05-17
ID28160A (id) 2001-05-10
PL345959A1 (en) 2002-01-14
CA2336945C (en) 2008-11-18
CN1319010A (zh) 2001-10-24
CN100400039C (zh) 2008-07-09
US6258849B1 (en) 2001-07-10
EA004179B1 (ru) 2004-02-26
KR20030027089A (ko) 2003-04-03

Similar Documents

Publication Publication Date Title
US6258849B1 (en) Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
KR20120027371A (ko) Ｄｏｐａ 데카르복실라제 억제제의 연속투여용 조성물
US9987301B2 (en) Heparin-based compositions and methods for the inhibition of metastasis
HK1037142B (en) Phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate for the treatment of neoplastic diseases
Cedarbaum et al. Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys
US4918193A (en) Methods for preparing 3-[N-phenyl-acetylaminopiperidine]-2,6-dion
MXPA99000255A (en) Treatment regimen for the administration of phenylacetilglutamine, phenylacetilisoglutamine and / or fen acetate
US20020187137A1 (en) S-methylcysteine, S-ethylcysteine, and related S-alkylthiols as antagonists to the effects of S-nitrosothiols and nitric oxide
EP1649855A1 (en) Medicinal composition
WO2025073968A1 (en) Combination of roginolisib with a malt1-gls inhibitor
HK1074771A (en) Use of composition in the manufacture of a medicament for treating neoplastic disease
TO et al. Metabolic Aspects and Medical Treatment for Urinary Tract Stones
LL0S0 et al. PRECLINICAL STUDIES ON ANTINEOPLASTON AS2-1 AND